SCYX earnings date and last-quarter result: next report 2026-08-12, last quarter miss, P/E -1.10. Updated 2026-07-23.
SCYNEXIS (SCYX) Research Hub
SCYNEXIS (SCYX) trades on NASDAQ, US in the Healthcare (Medical - Pharmaceuticals) sector. As of 2026-10-26, shares last closed at 3.81 USD (+0.66%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.10, market cap 0.03B. This hub links to the full technical, earnings and options research available for SCYX.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Medical - Pharmaceuticals) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 3.81 USD (+0.66%) |
| 52-week range | 3.53 USD – 6.09 USD |
| Trend regime | Range |
| 14-day RSI | 13.5 (Oversold) |
| Trailing P/E | -1.10 |
| Market cap | 0.03B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-12 |
Available research for SCYX
Covered Call on SCYX: how it works, illustrative setup around the real 3.81 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on SCYX: how it works, illustrative setup around the real 3.81 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on SCYX: how it works, illustrative setup around the real 3.81 USD price, max profit/loss, breakeven and when to use it. Educational.
SCYX technical analysis: range, last 3.81 USD, RSI 13.5, 52w range 3.53 USD–6.09 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is SCYX in?
SCYNEXIS (SCYX) is classified under Healthcare (Medical - Pharmaceuticals), listed on NASDAQ, US.
Is SCYX in an uptrend or downtrend?
As of 2026-10-26, SCYX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is SCYX's trailing P/E ratio?
SCYX's trailing P/E is -1.10, with a market cap of 0.03B. See the earnings research page for full valuation detail.
When does SCYX next report earnings?
SCYX is next scheduled to report earnings on 2026-08-12.